Ask Me Anything (AMA)

#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration

In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it’s possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary.

• Topics overview [1:15];
• Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30];
• Peter’s views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30];
• Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00];
• Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00];
• Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45];
• Strength training with limited time: how to maximize results with intensity and efficiency [30:00];
• Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45];
• Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00];
• Peter’s current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45];
• Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and
• More.

#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

In this “Ask Me Anything” (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he’s covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated “peptides” common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, “research use only” labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.

• Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];
• What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];
• A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];
• Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];
• Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];
• SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];
• Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];
• Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];
• Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];
• CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];
• Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];
• BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];
• Other popular “gray market” peptides and why they mostly fail when under scrutiny [1:11:15];
• How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];
• Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];
• Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];
• Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];
• The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and
• More.

#385 – AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more

In this “Ask Me Anything” (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines.

• Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance [1:30];
• How health priorities and training strategies should evolve from early adulthood through older age [2:45];
• Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00];
• Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00];
• How to use wearable data effectively: when it’s helpful, when it’s not, and how to avoid over-reliance [19:00];
• DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00];
• Best practices for building sustainable health habits [30:15];
• How to train your balance and stability [33:30];
• How to recover from injuries and use setbacks to build strength and resilience [36:15];
• High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30];
• Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00];
• How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and
• More.

#383 ‒ AMA #81: Biological aging tests, longevity training, emerging therapies, GLP-1 RAs, sun exposure, and more

In this “Ask Me Anything” (AMA) episode, Peter answers listener questions that pull back the curtain on how he actually thinks and operates across a wide range of topics in health and longevity. He explores whether biological aging clocks are truly trustworthy and how to assess if you’re aging well, how he thinks about seed oils, and the areas of research that most excite him right now, including cognitive health, GLP-1–based therapies, and other emerging interventions. Peter also dives into the potential upside of GLP-1s beyond weight loss and what evidence would justify broader use, explains why transcranial magnetic stimulation is on his radar, and shares his framework for evaluating body fat percentage. He walks through how he onboards a new patient without overwhelming them, reflects on the highest-leverage changes in his own life and the biggest training mistakes he’s made, and discusses sun exposure, skin cancer risk, photoaging, vitamin D, and circadian rhythm. Finally, he covers what he’s changed his mind on recently, explains why he doesn’t put much stock in “blue zones,” and much more.

• The value of biological aging tests, and why physical performance remains the most reliable marker [2:30];
• Seed oils: evaluating the evidence and separating dietary quality from ingredient fear [6:45];
• Emerging therapies Peter is excited about: lithium orotate for Alzheimer’s disease, potential geroprotective benefits of GLP-1s, transcranial magnetic stimulation, and more [9:30];
• Body fat percentage and longevity: balancing metabolic health, fat distribution, performance goals, and individual set points [16:45];
• Explaining metabolic flexibility and how it can be improved [20:30];
• How Peter onboards new patients, and how he thinks about the relative influence of genetics versus lifestyle on longevity and disease risk [24:30];
• The potential for AI to improve medicine [30:00];
• Valuable lessons Peter has learned from training mistakes [33:15];
• Balancing the risks and benefits of sun exposure [35:30];
• Specific examples of what Peter is doing to prepare for his Centenarian Decathlon [39:30];
• Strong convictions loosely held: evolving views on GLP-1 cardiovascular benefits, zone 2 training misconceptions, sauna temperature, and practical recovery priorities [43:30];
• Blue Zones under scrutiny: statistical outliers, data reliability concerns, genetics, and separating longevity correlation from causation [48:15]; and
• More.

#382 ‒ AMA #80: Longevity optimization through strength benchmarks, VO₂ max targets, nutrition principles, brain health, supplements, GLP-1 RAs, wearables, and more

In this special “Ask Me Anything” (AMA) episode, Peter answers a wide range of questions spanning the topics that come up most often in conversations about longevity and health optimization. He discusses which strength and power benchmarks matter most for long-term health, how beginners or time-constrained individuals can start exercising effectively, and why VO₂ max targets reflect planning for the life you ultimately want to live rather than overly aggressive goals. Peter explores the roles of exercise, sleep, and metabolic health in reducing the risk of cognitive decline and dementia, clarifies common misconceptions about insulin resistance and how to detect it earlier, and examines which supplements may be worth considering versus those that are likely noise. He also explains how GLP-1 medications work and where the evidence continues to evolve, how to use wearable health technology productively without increasing anxiety, practical strategies for improving sleep as a foundational pillar of healthspan, and much more.

• What strength and power metrics matter most for longevity and how to measure and track them [2:45];
• How beginners with limited time should start exercising for longevity [9:30];
• Exercise and lifestyle strategies for brain health [12:30];
• Misconceptions about insulin resistance and strategies for early detection [21:00];
• Supplements that warrant consideration [25:30];
• GLP-1 medications and the future of obesity treatment: efficacy, safe dosing strategies, metabolic benefits, and emerging therapies [28:45];
• Potential benefits of GLP-1 medications beyond weight loss: geroprotection, brain health, and more [33:15];
• How to use wearable devices effectively while avoiding anxiety, overdependence, and misinterpretation of imperfect data [38:30];
• Sleep as the foundation of health: why it comes first and practical strategies for improving circadian rhythm and sleep quality [44:15];
• VO₂ max targets for longevity: backcasting from late-life physical goals and planning for predictable age-related fitness decline [48:45];
• Peter’s longevity-focused nutrition principles [52:15];
• The three most important drivers of healthspan: sleep, exercise, and emotional health [56:45]; and
• More.

#379 – AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independence

In this “Ask Me Anything” (AMA) episode, Peter brings together his most up-to-date thinking on cardiorespiratory fitness into a single, practical guide designed to help listeners structure training for maximal impact on healthspan, lifespan, and long-term independence. He explains why cardiorespiratory fitness is one of the strongest modifiable predictors of longevity, clarifies what zone 2 training actually represents and how it differs from higher-intensity work, and addresses persistent confusion around exercise volume, intensity, and time constraints. The discussion covers how to measure and track progress in zone 2, VO₂ max targets and age-adjusted goals, planning for the marginal decade, and how to balance zone 2 with higher-intensity training across different weekly volumes. Peter also outlines how cardio training should be tailored for beginners, experienced trainees, and older adults, with special considerations for women and guidance on avoiding the most common cardio-training mistakes.

• Rational for discussing cardiorespiratory fitness, zone 2, and VO₂ max despite having covered the topic extensively [2:30];
• Why cardiorespiratory fitness and VO₂ max are powerful and modifiable predictors of all-cause mortality compared with other health metrics [7:30];
• How age-related declines in VO₂ max constrain healthspan and everyday physical function [12:30];
• The cardiorespiratory fitness triangle: how different training intensities contribute to building the aerobic base, the aerobic peak, and overall aerobic capacity [14:15];
• The cellular mechanics of cardiorespiratory fitness: mitochondria, lactate, muscle fiber recruitment, and intensity thresholds [18:45];
• The debate over whether zone 2 training has unique benefits or whether higher-intensity exercise alone is sufficient [27:15]; 
• Balancing intensity and sustainability as training volume increases, and the important role of zone 2 training [32:15];
• How to identify your zone 2 training intensity [34:45];
• How to measure and track improvements in zone 2 fitness [40:00];
• How to accurately measure VO₂ max: lab testing, field tests, and the limits of wearables [45:15];
• How to set meaningful VO₂ max targets based on age, sex, long-term decline, and desired physical capabilities later in life [51:15];
• How to structure and execute a zone 2 workout [59:45];
• How strictly should zone 2 be maintained during a workout? [1:04:00];
• How to design a VO₂ max training session: interval length, intensity, recovery, and progression strategies [1:07:00];
• Why heart rate is not a reliable metric for titrating VO₂ max interval intensity [1:12:00];
• Practical ways to monitor VO₂ max improvements [1:13:30];
• How to balance zone 2 and VO₂ max training [1:15:30];
• How to structure training for someone limited to 150 minutes per week of total exercise [1:19:00];
• How to allocate 150 minutes per week of dedicated cardiorespiratory training between zone 2 and VO₂ max work [1:23:00];
• How to structure training for someone with substantial available time who wants to maximize cardiorespiratory fitness [1:24:30];
• Why spreading aerobic training across the week beats compressing volume into one session [1:26:15];
• How beginners and metabolically unhealthy individuals should start cardiorespiratory training safely [1:28:00];
• How “training age” determines the intensity and workload needed to continue improving cardiorespiratory fitness [1:31:15];
• Why zone 2 training still matters for women (including postmenopausal women) [1:32:45];
• How cardiorespiratory training should adapt with aging [1:35:45];
• The most common mistakes people make when training cardiorespiratory fitness and how to avoid them [1:37:45];
• How to break through a VO₂ max plateau [1:40:45];
• The main takeaways about cardiorespiratory fitness and longevity [1:41:30];
• Peter’s carve out: oral hygiene and Peter’s two-toothbrush system [1:43:00]; and
• More.

#376 – AMA #78: Longevity interventions, exercise, diagnostic screening, and managing high apoB, hypertension, metabolic health, and more

In this “Ask Me Anything” (AMA) episode, Peter tackles a wide-ranging set of listener questions spanning lifespan interventions, exercise, cardiovascular risk reduction, time-restricted eating, blood pressure management, hormone therapy, diagnostics, and more. Peter reveals the single most important lever for extending healthspan and lifespan, and explains how he motivates midlife patients using the Centenarian Decathlon framework. He discusses the importance of addressing high apoB and cholesterol even in metabolically healthy individuals with calcium scores of zero, how to manage high blood pressure, and how to accurately evaluate metabolic health beyond HbA1c. Additional topics include time-restricted eating, practical considerations around ultra-processed foods, nuanced approaches to HRT for women and TRT for men, and why early and expanded screening for chronic disease—colonoscopy, PSA, coronary imaging, low-dose CT—can be lifesaving. He also offers insights into treating prediabetes, crafting exercise programs for those short on time, and safely incorporating high-intensity training in older adults.

• Introducing a wide-ranging AMA: practical perspectives on lifespan interventions, metabolic health, diet, hormones, diagnostics, and more [2:45];
• Why exercise is the most powerful single intervention for lifespan and healthspan [4:15];
• How Peter motivates midlife patients to prioritize exercise [6:00];
• Why lifespan and healthspan should not be treated as competing priorities and how choosing sustainable interventions benefits both [9:30];
• Why high apoB deserves treatment even in a metabolically healthy patient with a CAC score of zero [14:00];
• Managing hypertension: ideal targets for blood pressure, lifestyle levers, and why early pharmacology matters [18:15];
• Assessing metabolic health beyond HbA1c: fasting insulin, triglycerides, lactate, zone 2, and more [23:30];
• How to avoid common self-sabotaging patterns by choosing sustainable habits over extreme health interventions [26:00];
• Time-restricted eating: minimal effect beyond calorie control, implications for protein intake, and practical considerations for implementing it [28:00];
• Ultra-processed foods: definitions, real-world risks, and practical guidelines for smarter consumption [30:30];
• How women should prepare for menopause and think about hormone replacement therapy: early planning, symptom awareness, and guidance on HRT [36:45];
• Testosterone replacement for aging men: indications, benefits, and safe clinical management [39:45];
• Why Peter recommends earlier and more aggressive screening tests than guidelines suggest: colonoscopies, coronary imaging, PSA, Lp(a), and low-dose CT scans, and more [43:30];
• Full-body MRI screening: benefits, limitations, potential false positives, and the importance of physician oversight [47:15];
• Prediabetes: individualized treatment strategies using tailored combinations of nutrition, sleep, and training interventions [51:00];
• Time-efficient training plans for people with only 30 minutes per day to exercise [53:00];
• How to safely introduce high-intensity exercise for older adults [55:00];
• Timed dead hangs and ripping phone books: a playful look at Peter’s early attempts to impress his wife [57:15];
• Peter’s carve out: The Four Kings documentary about a golden era of boxing [1:01:15]; and
• More.

#370 – AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — proven, promising, fuzzy, noise, or nonsense?

In this “Ask Me Anything” (AMA) episode, Peter revisits the “proven, promising, fuzzy, noise, nonsense” framework and applies it to a variety of popular topics. He begins with a refresher on what each category represents before classifying a range of interventions based on the strength of their supporting evidence. The conversation spans three main areas: drugs for geroprotection (including GLP-1 agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements), the use of low-dose aspirin for cardiovascular disease prevention, and strategies to improve muscle mass through optimal protein intake and follistatin gene therapy. This episode provides a clear, evidence-based overview for listeners seeking to understand where these popular health and longevity interventions stand on the spectrum of scientific credibility.

• A framework for evaluating scientific claims: proven, promising, fuzzy, noise, or nonsense [A: 1:30, V: 0:10];
• Strong convictions, loosely held: the mindset that separates great scientists from the rest [A: 7:30, V: 6:30];
• GLP-1 agonists: are there benefits beyond improving metabolic health and promoting weight loss? [A: 12:45, V: 12:25];
• GLP-1 drugs and the brain: exploring the potential cognitive benefits [A: 18:45, V: 18:55];
• GLP-1 drugs and lifespan: examining the evidence for potential geroprotective effects [A: 23:00, V: 23:45];
• Rapamycin and geroprotection: why it remains in the “promising” category [A: 25:45, V: 26:50];
• SGLT2 inhibitors and their potential geroprotective effect [A: 27:30, V: 28:40];
• Methylene blue: examining the evidence of an anti-aging effect [A: 34:45, V: 37:00];
• Methylene blue’s potential neuroprotective effects: limited and inconsistent evidence in humans, and the challenges of dosing and safety [A: 41:15, V: 43:45];
• Telomeres: what they are, how they relate to aging, and why telomere-lengthening supplements lack credible scientific evidence [A: 43:45, V: 47:26];
• Does the idea of targeting telomere length to extend lifespan have scientific merit? [A: 50:15, V: 54:45];
• Low-dose aspirin for cardiovascular disease prevention: weighing its clot-prevention benefits against bleeding risks across different populations [A: 55:00, V: 1:00:05];
• Rethinking the protein RDA: why most people need twice the recommended amount for muscle health [A: 1:00:45, V: 1:06:40];
• Debunking the protein–cancer myth: why higher protein intake doesn’t promote tumor growth [A: 1:06:15, V: 1:12:40];
• The biology of follistatin and myostatin, and why follistatin gene therapy has become an emerging topic of interest for muscle growth [A: 1:13:15, V: 1:20:50];
• Follistatin gene therapy for muscle growth: state of the evidence in animals and humans, and the technical challenges and regulatory barriers [A: 1:17:00, V: 1:25:05];
• Why injectable follistatin is theoretically possible but impractical for real-world use [A: 1:23:15, V: 1:32:30]; and
• More.

#367 – Tylenol, pregnancy, and autism: What recent studies show and how to interpret the data

In this special episode of The Drive, Peter addresses the recent headlines linking acetaminophen (Tylenol) use during pregnancy to autism in exposed children. Recognizing the confusion these claims have sparked among patients, listeners, and the broader public, Peter uses this episode to provide a framework for thinking critically about complex conditions and the research related to them. He highlights the dramatic rise in autism diagnoses over recent decades, noting that multifactorial conditions rarely have a single cause, and emphasizes the importance of resisting oversimplified explanations. Peter also stresses that humans are not naturally wired for scientific thinking, making disciplined frameworks like the Bradford Hill criteria essential for evaluating causality in epidemiology. Ultimately, he uses this framework to explore the evidence surrounding acetaminophen use during pregnancy and its potential link to autism.

• Laying the groundwork for this discussion, the rise in autism rates, and the value in using frameworks [A: 1:00, V: 0:09];
• The FDA pregnancy drug categories, where Tylenol falls within that framework, and a structured method for evaluating scientific evidence and causality [A: 6:00, V: 5:33];
• What exactly are the claims being made about acetaminophen and autism? [A: 13:45, V: 14:13];
• The increase in autism rates and why so many things are being linked to autism: the multiple comparisons problem [A: 15:00, V: 15:27];
• Evaluating the review paper that triggered the recent concern over acetaminophen and autism [A: 21:45, V: 22:34];
• Breaking down the largest studies on prenatal Tylenol exposure and autism: is there a causal link? [A: 35:00, V: 36:20];
• Why observational studies can’t prove causality, the role of confounding variables, and the importance of frameworks like the Bradford Hill criteria [A: 43:30, V: 45:08];
• Applying the Bradford Hill criteria: testing the case for Tylenol and autism [A: 45:45, V: 47:48];
• Putting it all together to answer the question: Does acetaminophen use during pregnancy increase the risk of autism? [A: 56:15, V: 59:03];
• If autism risk is overwhelmingly genetic, what explains the dramatic rise in autism diagnoses? [A: 59:15, V: 1:02:09];
• Other risk factors for autism: parental age, maternal health, environment, and where Tylenol fits in [A: 1:09:15, V: 1:12:41];
• Medication use during pregnancy: balancing risks, benefits, and FDA categories [A: 1:15:15, V: 1:19:01];
• Considerations for taking Tylenol during pregnancy [A: 1:19:30, V: 1:23:48];
• Final thoughts: critical thinking, balanced risk assessment, and the importance of context when evaluating medications like Tylenol during pregnancy [A: 1:22:30, V: 1:26:53]; and
• More.

#364 – AMA #75: Diets: how to evaluate and implement any diet including keto, carnivore, vegan, Mediterranean, and more

In this “Ask Me Anything” (AMA) episode, Peter explores how to determine the right diet for yourself rather than searching for a universal “best” diet. He begins by laying out five non-negotiable criteria that any sustainable eating pattern must meet—energy balance, metabolic health, adequate protein, micronutrient sufficiency, and long-term adherence—before introducing a practical rubric for evaluating different diets. Using this framework, Peter walks through the ketogenic, carnivore, vegan, and Mediterranean diets, highlighting their strengths, ideal candidates for each, and common pitfalls such as micronutrient gaps or adherence challenges. He explains why this guidance is aimed at people who feel overwhelmed by diet choices, not zealots defending a single approach, and provides practical advice on using tools like DEXA scans, lab markers, continuous glucose monitors, and symptom tracking to assess whether a diet is truly working.

• Peter’s family chess battle [A: 3:00, V: 1:27];
• Framing the diet discussion: moving past tribalism to practical frameworks for evaluating various dietary strategies [A: 5:00, V: 3:45];
• Peter’s high-level nutrition framework [A: 11:00, V: 1:20];
• Why diet is such a uniquely polarizing subject [A: 14:15, V: 14:15];
• The five non-negotiables that apply to any diet [A: 17:45, V: 18:23];
• How to think about energy balance in the context of evaluating a specific diet [A: 20:15, V: 21:10];
• How diet can address metabolic health [A: 21:45, V: 22:56];
• Protein as a dietary foundation [A: 23:30, V: 25:15];
• Micronutrient essentials: avoiding deficiencies in restrictive and processed diets [A: 24:45, V: 26:36];
• Why adherence and sustainability are essential for diet success [A: 27:15, V: 29:21];
• Examining the standard American diet through the five non-negotiables [A: 31:00, V: 33:57];
• The evaluation framework for specific diets [A: 33:30, V: 37:00];
• The ketogenic diet: defining ketosis, clinical origins, modern uses, and potential health benefits [A: 35:00, V: 38:33];
• The main strengths and weaknesses of the ketogenic diet [A: 43:00, V: 48:00];
• How to avoid micronutrient deficiencies while on a ketogenic diet [A: 47:15, V: 52:49];
• Electrolytes and fiber and the ketogenic diet: preventing magnesium loss and maintaining digestive health [A: 49:15, V: 55:22];
• Adherence challenges of the ketogenic diet [A: 51:30, V: 58:00];
• The carnivore diet: definition, motivations, anecdotal benefits, and possible mechanisms [A: 53:15, V: 59:58];
• The main strengths and weaknesses of the carnivore diet [A: 57:30, V: 1:05:03];
• Plant exclusion on the carnivore diet: nutrient gaps, gut changes, and unanswered questions [A: 1:03:15, V: 1:12:38];
• Adherence challenges of the carnivore diet [A: 1:04:45, V: 1:14:28];
• The vegan diet: definition, core beliefs, and various motivations for this strategy [A: 1:05:45, V: 1:15:46];
• The main strengths and weaknesses of the vegan diet [A: 1:09:15, V: 1:20:15];
• Adherence to the vegan diet: social acceptance, edge cases, and personal sustainability [A: 1:13:15, V: 1:24:40];
• The Mediterranean diet: definitional challenges, traditional patterns, and its relatively strong evidence base [A: 1:15:15, V: 1:26:57];
• Limitations of the Mediterranean diet: loose definitions and indulgence risks [A: 1:19:30, V: 1:31:45];
• Measuring diet success: why setting clear goals and tracking outcomes matter [A: 1:21:00, V: 1:33:51];
• Tracking body composition using DEXA scans [A: 1:22:15, V: 1:35:27];
• Tracking metabolic health: key blood tests and advanced glucose monitoring tools [A: 1:22:45, V: 1:36:07];
• Using elimination diets to identify food sensitivities that may cause digestive problems, autoimmune symptoms, or low energy [A: 1:23:30, V: 1:36:45];
• Evaluating “anti-inflammatory diets”: confirming inflammation through symptoms and hs-CRP testing [A: 1:25:15, V: 1:38:54];
• Final takeaways: flexibility, structure, and avoiding dogma in dietary choices [A: 1:27:00, V: 1:40:49]; and
• More.

#361 – AMA #74: Sugar and sugar substitutes: weight control, metabolic effects, and health trade-offs

In this “Ask Me Anything” (AMA) episode, Peter explains how to evaluate sugar and its substitutes in the context of health. Peter explores the role of sweeteners in three common use-cases – beverages, protein supplements, and sweet treats – and breaks down how our evolutionary craving for sweetness now clashes with today’s food environment. He examines whether sugar is uniquely fattening, the hormonal effects of sugar consumption, and the significance of timing in sugar intake. The episode compares natural versus refined sugars, sugar in beverages versus in solid foods, and the pros and cons of popular sweeteners including saccharin, aspartame, sucralose, allulose, and sugar alcohols like erythritol and xylitol. With a focus on weight management, glycemic impact, gut health, and long-term safety, this episode offers a comprehensive guide to navigating the sweetener landscape with clarity and nuance.

• A quick tangent on chess and parenting [A: 2:30, V: 1:00];
• Overview of key scenarios for evaluating sugar and sweeteners [A: 6:15, V: 5:15];
• Why humans are hardwired to crave sweetness [A: 13:30, V: 13:15];
• Evaluating whether sugar is uniquely fattening or more harmful than other macronutrients under isocaloric conditions [A: 15:15, V: 15:15];
• Why sugar drives appetite: low satiety, insulin response, and reward system activation [A: 18:45, V: 19:15];
• How sugar type, liquid vs. solid form, and processing level influence appetite and metabolic impact [A: 20:15, V: 21:15];
• Addressing the common belief that natural sugars are healthier than refined sugars [A: 26:00, V: 27:45];
• How the timing of sugar consumption alters the body’s metabolic response [A: 29:15, V: 31:55];
• How Peter advises patients on sugar intake, factoring in metabolic health, insulin sensitivity, and activity level [A: 34:45, V: 38:00];
• The most common sugar substitutes, their sweetness relative to sugar, and their caloric content [A: 36:30, V: 40:20];
• Evaluating the role of sugar substitutes in weight control: efficacy vs. effectiveness and limitations in study design [A: 40:15, V: 44:30];
• Assessing the real-world impact of sugar substitutes on weight, and the role of sweetness without calories [A: 44:00, V: 48:50];
• The impact of sugar substitutes on glycemic control [A: 47:30, V: 52:50];
• Are microbiome changes from artificial sweeteners substantial enough to cause obesity and diabetes? [A: 50:30, V: 56:30];
• How Peter advises patients on the use of sugar substitutes across different contexts [A: 52:30, V: 58:45];
• Allulose—a sweetener with unique satiety and glycemic benefits and potential for weight control [A: 57:15, V: 1:04:30];
• Emerging evidence that stevia, monk fruit, and sugar alcohols may provide modest metabolic benefits compared to sugar [A: 1:03:00, V: 1:10:45];
• Sugar alcohols explained [A: 1:04:15, V:1:12:20];
• Xylitol’s dental health benefits and considerations for use [A: 1:05:00, V: 1:13:20];
• Artificial sweeteners and cancer risk: evaluating evidence, the aspartame controversy, and the role of dose in toxicology [A: 1:07:15, V: 1:15:55];
• Sugar substitutes and cardiovascular disease: assessing flawed studies and the absence of direct risk evidence [A: 1:11:00, V: 1:20:15];
• Why artificial sweeteners seem to attract so many negative headlines [A: 1:12:45, V: 1:22:05];
• Balancing benefits and risks of sugar substitutes: guidance for desserts, beverages, and protein products [A: 1:14:15, V: 1:24:00]; and
• More.

356 – AMA #73: Preserving brain health, optimizing exercise programming, improving body composition, and more

In this “Ask Me Anything” (AMA) episode, Peter addresses frequently requested topics, including brain health, exercise programming, and body composition. He explores the factors that influence dementia risk—including metabolic health, fitness, sleep, hearing, cholesterol levels, and more. He explains how to implement zone 2 training and VO₂ max intervals for cardiovascular fitness and also covers how to combine cardio modalities, how to stay in zone 2, and special considerations for women. Peter highlights the benefits of light movement after meals and offers strength training tips for those managing injuries. Additional insights include how to maintain fat loss, the truth about so-called “slow metabolisms,” and how to set appropriate daily protein goals while managing the trade-off between lean mass and body fat over time.

• Overview of episode topics on brain health, cardiovascular training strategies, and body composition [2:15];
• Understanding dementia risk: modifiable vs. non-modifiable contributors to cognitive decline [5:00];
• The causality between metabolic health and dementia [9:45];
• How diet and exercise influence brain health: energy balance and exercise as key preventative tools [13:30];
• Why combining aerobic, resistance, and cognitively engaging activities offers the most comprehensive benefits for preventing cognitive decline [17:00];
• Additional lifestyle factors that influence dementia risk: smoking, head trauma, alcohol, and sleep [19:45];
• The link between hearing loss and dementia: dose-dependent risk and the case for correction [25:15];
• How poor oral hygiene may contribute to neuroinflammation and dementia risk [23:30];
• Supplements for brain health: which ones matter and when they’re worth considering [28:45];
• Low LDL cholesterol and brain health: debunking the myth of cognitive risk [33:45];
• How to approach zone 2 training: the importance of staying in zone 2 and tailoring intensity based on your time and goals [38:00];
• Lactate testing for zone 2: clinical protocols and at-home approaches [43:00];
• Combining modalities in zone 2 training: balancing enjoyment and efficiency [47:00];
• Zone 2 training for women: addressing the misconception that zone 2 training is unnecessary or ineffective for postmenopausal women [49:30];
• Effective strategies for VO₂ max training: short vs. long intervals [51:45];
• The benefits of post-meal walking for glucose management, and why spikes in glucose during exercise aren’t harmful [56:45];
• The role of stability training in supporting resistance work and healthy aging [1:00:15];
• Adapting strength training to manage chronic back injuries and train for longevity [1:02:00];
• The role of aerobic exercise (like zone 2) in fat loss, metabolic health, and weight maintenance [1:06:30];
• Debunking the “fast vs. slow metabolism” myth: why energy balance and protein matter most for fat loss [1:09:45];
• Lean mass vs. body fat: why both matter for health and longevity [1:12:15];
• How protein intake impacts muscle mass and why pairing it with resistance training is significantly more effective [1:15:15]; and
• More.

#353 – AMA #72: Fasting: benefits for body composition and disease prevention, potential risks, and Peter’s updated practical framework

In this “Ask Me Anything” (AMA) episode, Peter revisits the topic of fasting, sharing how his thinking has evolved over time. The episode explores fasting-related terminology and common types of fasting, as well as the various reasons individuals might choose to fast. Peter explores potential benefits including improvements in body composition, metabolic health, lifespan extension, cardiovascular disease, cancer prevention and treatment, neurodegenerative conditions such as Alzheimer’s and Parkinson’s, and autoimmune symptoms like arthritis. He also examines the risks and potential downsides of fasting and offers a practical framework to help assess when and how fasting may be most appropriately applied.

• Why the topic of fasting is being revisited [1:45];
• The importance of being open to changing one’s opinion in science and medicine as new evidence emerges [4:15];
• Defining fasting and how it fits in the framework of dietary restriction, time-restricted feeding, and calorie restriction [7:30];
• The most common types of fasting [11:45];
• Why someone might choose fasting over continuous caloric restriction [19:00];
• The biochemical effects of fasting: fuel partitioning, autophagy, and more [21:00];
• Autophagy: a cellular cleanup process stimulated by fasting and energy depletion [26:00];
• Comparing the physiological effects of a ketogenic diet to those of long-term fasting [27:45];
• How long fasting takes to induce ketosis and boost autophagy, and how autophagy is measured [29:45];
• At-home tests for ketones [33:45];
• Reducing senescent (“zombie”) cells and inflammation through autophagy [35:00];
• Examining the evidence for the long-term health benefits of fasting beyond short-term metabolic effects [37:15];
• The common health claims associated with fasting across metabolic, neurological, oncological, autoimmune, and longevity domains [40:30];
• The impact of fasting on body weight and body composition [42:00];
• Weight regain and potential metabolic consequences of fasting [44:00];
• The risk of lean mass loss with fasting and how to mitigate it [47:15];
• A practical framework for using fasting as a strategy to improve body composition [52:15];
• How extended fasting compares to caloric restriction in improving insulin sensitivity in people with insulin resistance or type 2 diabetes [54:00];
• Is there any evidence that fasting can extend lifespan? [55:45];
• Examining whether fasting improves cardiovascular disease risk beyond the effects of weight loss and calorie reduction [58:15];
• Exploring whether prolonged fasting can reduce cancer risk [59:45];
• The potential benefits of fasting or fasting-mimicking diets during cancer treatment: emerging evidence and practical considerations [1:02:15];
• Fasting for protection against neurodegenerative diseases: early evidence of therapeutic benefit and open questions [1:10:45];
• Various fasting methods for autoimmune diseases: potential symptom relief with cautious application [1:14:00];
• Fasting and type 1 diabetes: risks, evidence, and careful dietary alternatives [1:16:45];
• Fasting and gut disorders: potential benefits outside of flare-ups [1:18:45];
• The primary risks and downsides associated with fasting [1:19:45];
• The essential vitamins and minerals to supplement during prolonged fasting [1:21:30];
• Who should avoid fasting and why [1:22:15];
• Fasting’s role in health: where it shows promise and where it likely offers no distinct advantage over caloric restriction [1:23:45]; and
• More.

#349 – AMA #71: Building strength and muscle mass: how to optimize training, nutrition, and more for longevity

In this “Ask Me Anything” (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably.

• Peter’s humorous experience talking nutrition with a second grader [2:30];
• Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:00];
• Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:15];
• The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [10:30];
• Grip strength as a simple yet powerful predictor of all-cause mortality [16:45];
• Is muscle strength causal or just a marker of health? [20:00];
• Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [22:30];
• How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [23:45];
• How muscle mass and strength decline with age, and why it’s essential to act early to slow decline and preserve function later in life [30:30];
• The foundational principles of building muscle strength and size through resistance training [35:30];
• How to apply “progressive overload” for long-term strength and muscle gains [39:30];
• The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [44:45];
• The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:15];
• How to effectively train for power [52:00];
• Training intensity: the benefits and safety of using the “reps in reserve” method [53:00];
• How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [55:45];
• Can bodyweight exercises build muscle as effectively as weight training? [57:45];
• How women can effectively build strength and muscle: key considerations [59:15];
• Effective methods for tracking progress in strength [1:01:15];
• Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:04:30];
• How to balance workout frequency with recovery for optimal results [1:06:45];
• How to recognize signs of overtraining and when to consider taking rest days [1:10:15];
• Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:15];
• Protein: recommended intake, quality sources, timing of consumption, and more [1:17:30];
• How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:15];
• Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:27:45];
• The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:28:45];
• How to structure an effective workout routine for a younger person that is new to resistance training [1:31:30];
• How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:35:30];
• Should beginners start with machines or free weights when resistance training? [1:36:30];
• How experienced lifters should modify their training to support healthspan and performance in later life [1:38:00]; and
• More.

#344 – AMA #70: Nicotine: impact on cognitive function, performance, and mood, health risks, delivery modalities, and smoking cessation strategies

In this “Ask Me Anything” (AMA) episode, Peter dives deep into nicotine—a topic increasingly debated both scientifically and publicly. He clarifies the critical differences between nicotine and tobacco, highlighting why nicotine alone isn’t primarily responsible for smoking’s severe health consequences. Peter examines the specific risks associated with nicotine use, including addiction, sleep disruption, cardiovascular concerns, and effects on mood and anxiety. He evaluates various nicotine delivery methods, from traditional cigarettes to gums, pouches, and synthetic alternatives, ranking them according to their relative safety. Additionally, Peter explores nicotine’s potential positive and negative impacts on physical performance, cognitive function, fertility, and its interactions with other stimulants like caffeine. Finally, he provides practical guidance for minimizing risks with nicotine use and offers thoughtful strategies for smoking cessation and effective nicotine replacement therapies.

• Revisiting the previous AMA on microplastics: low-effort, high-impact changes to significantly reduce microplastic exposure [1:45];
• Overview of episode topics related to nicotine [3:30];
• The current landscape of nicotine research [4:45];
• Addressing the common misconception that nicotine itself is the primary cause of tobacco-related health risks [6:45];
• Peter’s Marlboro-branded apparel is a nostalgic tribute to the Formula One era and not a sign of support for smoking [10:00];
• The limitations of current research on the health risks of nicotine itself [12:15];
• The most common side effects of nicotine [18:15];
• The impact of nicotine on sleep [21:30];
• Nicotine and mood: how nicotine can have both anxiety-inducing and calming effects based on genetics and dosage [25:00];
• The addictive properties of nicotine: factors influencing addiction risk, and why certain people may struggle more than others [29:15];
• The various nicotine products and nicotine delivery methods available: effects, absorption rates, and potential risks [33:45];
• The relative risks of various nicotine products: how differences in nicotine concentration, absorption rates, and presence of contaminants impact their safety [37:00];
• How nicotine exposure during adolescence can negatively impact brain development [47:45];
• Nicotine’s potential to prevent or slow neurodegenerative diseases [50:45];
• Nicotine’s impact on memory, learning, and attention [52:45];
• The interaction between nicotine and other stimulants, particularly caffeine [55:15];
• Nicotine’s potential impact on physical performance [57:15];
• The potential effects of nicotine on fertility, and the challenges of distinguishing the impact of nicotine itself from the effects of smoking [58:30];
• Considerations for people curious about using nicotine for its cognitive benefits [1:01:30];
• How to think about nicotine: weighing cognitive claims, addiction risks, and personal tolerance [1:03:15];
• The prevalence of smoking, the health risks it poses, and the substantial long-term benefits of quitting [1:05:45];
• Effective strategies for smoking cessation including the use of nicotine replacement therapies [1:09:00];
• The reasons behind weight gain after quitting smoking, the role of nicotine in appetite suppression, and strategies to manage weight [1:15:30]; and
• More.

#340 – AMA #69: Scrutinizing supplements: creatine, fish oil, vitamin D, and more—a framework for understanding effectiveness, quality, and individual need

In this “Ask Me Anything” (AMA) episode, Peter explores the complex world of supplements by introducing a practical framework for evaluating their effectiveness and relevance to individual health needs. Rather than providing a simple list of recommendations, Peter aims to equip listeners with the tools to critically assess supplements on their own. He then applies this framework to discuss research on several popular supplements, including creatine, fish oil, vitamin D, B vitamins, and ashwagandha. Additionally, he covers key factors in assessing supplement quality, helping listeners develop a deeper understanding of how to make informed decisions based on their personal health goals.

• Overview of episode topics [1:45];
• How Peter evaluates patients’ supplement regimens, and common misconceptions about supplements vs. pharmaceuticals [3:00];
• A framework for evaluating supplements [6:15];
• Evaluating creatine: purpose of supplementation, dosing, and mechanism of action [10:00];
• Creatine: proven benefits for muscle performance, potential cognitive benefits, and why women may benefit more [15:15];
• Creatine: risk vs. reward, kidney concerns, and choosing the right supplement [18:45];
• Evaluating fish oil: its primary purpose as a supplement and how to track levels [20:45];
• Fish oil: how omega-3s impact inflammation, heart health, and brain function, and the strengths and limitations of current research [26:30];
• Fish oil: the risks of supplementation, guidance on selecting high-quality products, and how to determine whether supplementation is appropriate [37:30];
• Evaluating vitamin D: understanding deficiency and optimal levels [45:15];
• Vitamin D: role in bone health, immune function, potential longevity impact, and biomarker limitations [51:15];
• Vitamin D: efficacy, safety, and balancing risk vs. reward [58:15];
• Evaluating B vitamins: function, consequences of deficiency, and key biomarkers to assess whether supplementation is necessary [1:02:15];
• B vitamins: risks for CVD and dementia associated with deficiency, and limited evidence for general population supplementation [1:07:15];
• Evaluating ashwagandha: background, uses, and mechanism of action [1:15:30];
• Ashwagandha: current evidence for its effects on sleep, stress, and anxiety [1:19:15];
• Ashwagandha: evaluating supplement quality, safety profile, and the risk-reward balance [1:22:15];
• The importance of using a structured evaluation framework to assess any supplement [1:26:30]; and
• More.

#336 – AMA #68: Fasting, well-balanced diets, alcohol, exercise for busy people, wearables, emotional health, assessing cardiovascular health, and more

In this “Ask Me Anything” (AMA) episode, Peter tackles a diverse set of listener-submitted questions, covering a wide range of health and performance topics. He dives into assessing cardiovascular health, discussing key biomarkers and risk factors, and breaks down various fasting approaches, including time-restricted eating and prolonged fasting. The conversation also explores the impact of alcohol on health and disease risk, fundamental principles of nutrition, and optimal protein intake. Additionally, he examines the pros and cons of ketogenic and low-carb diets, strategies for building effective exercise routines, and the role of wearables in tracking health metrics. The episode concludes with insights on emotional health, making this a well-rounded discussion packed with practical takeaways for anyone looking to optimize their well-being.

• Episode format: overview of common health topics based on listener questions [1:30];
• How to accurately assess your cardiovascular health [3:00];
• The impact of fasting, time-restricted eating, and dietary restriction on metabolic health [9:00];
• Alcohol: health risks of consumption, limitations of research, and how to weigh the risks against social and personal enjoyment [13:45];
• Principles of a well-balanced diet: macronutrients, micronutrients, protein, energy balance, and more [23:45];
• The benefits and drawbacks of ketogenic diets: impact on satiety, metabolic health, athletic performance, lipid levels, and more [29:15];
• Protein: best sources for muscle growth, total intake, PDCAAS scoring system, and getting adequate amounts on plant-based diets [36:15];
• Creating an effective fitness routine that fits into a busy schedule [41:45];
• The role of rest and recovery in a workout routine [46:00];
• How to track fitness progress beyond just weight on a scale [48:30];
• The best low-impact exercises for individuals with joint issues [52:00];
• Wearables: insight vs. compliance, and how to use them effectively [54:45];
• How to evaluate the risks and benefits of medical interventions: procedural risks, complication rates, and asking informed questions [59:00];
• Sleep: impact on metabolic and cognitive health, and tips for improving sleep quality [1:03:45];
• How to identify and address emotional health challenges [1:08:30]; and
• More.

#332 – AMA #67: Microplastics, PFAS, and phthalates: understanding health risks and a framework for minimizing exposure and mitigating risk

In this “Ask Me Anything” (AMA) episode, Peter tackles a topic that’s been dominating headlines and sparking widespread concern: microplastics and plastic-associated chemicals, including BPA, PFAS, and phthalates. Peter explores the science behind these substances including how and why they’ve become so prevalent, the extent of our exposure, and the potential risks to our health. Most importantly, he provides a practical framework for understanding microplastics and plastic-associated chemicals and minimizing exposure while distinguishing genuine risks from exaggerated concerns.

We discuss:

• The complexity of the topic of microplastics and associated chemicals [1:30];
• Definitions: microplastics, BPA, PM2.5, phthalates, and more [6:30];
• The reasons behind the increase in microplastics in our environment and the surge in interest in them [12:00];
• The various ways that humans are exposed to microplastics and nanoplastics [14:00];
• Volume of plastic consumed by humans, and how the body eliminates or absorbs microplastics [16:00];
• How microplastics accumulate in the body, the variability in tissue accumulation, and the challenges in studying their long-term health effects [21:30];
• Limitations of blood tests for microplastics, and the importance of reliable biomarkers for guiding behavior and interventions [26:30];
• The speculative health risks of microplastics, the limitations of current research, and the need for more robust studies [29:15];
• The challenges of measuring microplastics in human tissues, the need for better methodologies, and the importance of critically evaluating study relevance and claims [39:45];
• If it’s unclear whether microplastics actually cause harm, should we still be concerned about exposure? [42:15];
• Strategies to minimize microplastic exposure [45:00];
• The financial cost and effort involved in various microplastic exposure mitigation strategies [51:00];
• The role of airborne microplastics in total exposure and accumulation [1:03:00];
• Chemicals associated with plastics, their role as endocrine disruptors, and the challenges in linking exposure to specific health outcomes [1:04:00];
• BPA: role in plastic production, and its potential developmental risks [1:05:45];
• BPA’s potential health risks: pregnancy, fertility, obesity, and diabetes, and the socioeconomic confounders in the data [1:08:30];
• Regulatory limits on BPA exposure, and practical considerations for reducing exposure [1:12:45];
• The prevalence of BPA in modern products and how to identify it [1:17:15];
• PFAS: chemical structure and purpose in products [1:18:30];
• Why PFAS are considered endocrine disruptors [1:19:45];
• The main sources of PFAS exposure, and practical steps to reduce exposure [1:21:30];
• The potential health risks of PFAS exposure [1:24:00];
• Phthalates: role in making plastics flexible, and presence in personal care products [1:24:45];
• Why phthalates are considered endocrine disruptors [1:25:15];
• The main sources of phthalate exposure, and how manufacturing practices are evolving to reduce exposure [1:26:45];
• Practical strategies to reduce exposure to phthalates in food, air, water, and personal care products [1:28:30];
• Navigating microplastics and associated chemicals: a framework for personalized risk reduction [1:29:30]; and
• More.

#329 ‒ Special AMA: Peter on exercise, important labs, building good habits, promising longevity research, and more

In this special episode of The Drive, Peter tackles a wide range of listener questions submitted over the past year. The discussion spans essential topics such as exercise—covering grip strength, traveling workouts, and why Peter doesn’t consider exercise an ideal weight-loss strategy—and the top biomarkers everyone should track. He also explores promising new longevity research, his evolving views on longevity, and frameworks like “objective, strategy, tactics” for personalized decision-making. The episode wraps up with insights on building good habits and a glimpse into Peter’s recent reading list.

We discuss:

• Overview of episode topics (and Peter’s car stereo saga) [1:45];
• The importance of grip strength and the best methods for training it effectively [3:45];
• Exercise while traveling: strategies for staying active and maintaining an exercise routine [14:45];
• Why women should prioritize strength training [18:00];
• The limited role of exercise in weight loss and its greater importance in improving health, body composition, and insulin sensitivity [19:45];
• The “top five most important biomarkers” for assessing health [22:45];
• Promising developments in longevity research [28:15];
• The development of Klotho as a neuroprotective drug: challenges, timelines of trials, and more [34:00];
• Peter’s updated view on the potential of epigenome manipulation to restore aged cells to their youthful state [39:45];
• How reversing age-related epigenetic changes in immune cells could revolutionize our approach to aging and disease [43:30];
• The “objective, strategy, tactics” framework, and the importance prioritizing impactful lifestyle habits over less significant health trends [49:30];
• Strategies for building and maintaining good habits [56:45];
• How to think about drugs and supplements as part of a longevity toolkit [1:02:00];
• Peter’s recent reading list [1:05:15]; and
• More.

328 – AMA #66: Optimizing nutrition for health and longevity: myth of a “best” diet, complexities of nutrition science, and practical steps for building a sustainable diet

In this “Ask Me Anything” (AMA) episode, Peter dives deep into one of the most frequently discussed and often misunderstood topics: nutrition. From weight loss and maintenance to the intricate relationship between nutrition and exercise and body composition, Peter addresses the complexities of nutrition research and explores the perennial question of whether there is a “best diet.” He provides practical insights on how to choose the right diet for your unique needs, discusses the role of protein and processed foods, and outlines the key questions to help you optimize your approach to eating.

We discuss:

• The key nutrition-related topics to be discussed [1:30];
• Why Peter is not fond of discussing nutrition: limitations of nutrition research, the pitfalls of extreme certainty in dietary discussions, and the body’s adaptability to varied diets [3:30];
• Key health metrics to monitor to evaluate the effects of nutrition [9:30];
• The relationship between nutrition and exercise as they relate to weight loss, maintenance, and gain [12:30];
• How increased muscle mass from resistance training impacts calorie burn, body composition, glucose metabolism, and overall health benefits [19:45];
• Comparing the impact of fitness and nutrition on lifespan and healthspan: data showing fitness to be a more significant predictor of mortality than nutrition [23:30];
• The myth of a “best diet,” factors that determine the effectiveness of a diet, and data suggesting benefits of the Mediterranean diet [39:00];
• How long to trial a new diet, the importance of measurable goals, and the appropriate timescales for observing meaningful changes [48:30];
• The inherent challenges in nutrition research: variability in dietary exposures, limitations in study design, the body’s adaptive nature which dampen the effects, and more [51:15];
• Nutritional approaches for chronic diseases like cardiovascular disease and type 2 diabetes [58:45];
• Emerging studies on dietary interventions for non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) [1:02:45];
• Practical considerations for individuals to identify the best diet for them: protein intake, energy balance, macronutrient adjustments, and micronutrient levels [1:06:00];
• Understanding processed vs. ultra-processed foods [1:09:15];
• The effects of ultra-processed foods on health [1:12:30];
• Questions that someone should ask themselves if they’re looking to fine-tune their diet [1:18:15]; and
• More.

#326 – AMA #65: Red light therapy: promising applications, mixed evidence, and impact on health and aging

In this “Ask Me Anything” (AMA) episode, Peter dives into the world of red light therapy in response to frequent questions from listeners. Peter provides a comprehensive exploration, starting with the basics of red light therapy and why it’s getting so much attention. The conversation examines the latest data on various applications, including aging, skin health, acne, wound healing, hair loss, eye health, exercise performance, metabolic health, weight loss, inflammation, injury recovery, and menstrual cramps. Peter analyzes the scientific literature on each use case and concludes with a summary table that provides an easy-to-follow breakdown of the potential benefits of red light therapy across these areas.

We discuss:

• Overview of topics and the motivation behind exploring red light therapy [1:45];
• The basic science of red light therapy [3:15];
• The unique penetration properties of red light [6:00];
• What happens when tissue is exposed to red light [9:30];
• Exploring red light therapy’s potential to combat aging [11:00];
• Red light therapy for treating acne [13:00];
• Red light therapy for aiding in wound healing [18:45];
• Red light therapy for hair loss: promising benefits and practical advice [24:15];
• Analyzing the evidence of a positive or negative effect of red light therapy on the eyes [28:00];
• Red light therapy’s impact on performance and recovery [30:30];
• Red light therapy’s impact on metabolic health: analyzing the limited evidence for improved glucose metabolism [32:45];
• Red light therapy for weight loss and targeted fat reduction [36:45];
• Red light therapy for inflammation, chronic pain, and injury rehabilitation [41:00];
• Red light therapy as a treatment for menstrual cramps [43:45];
• Summary: promising applications of red light therapy, unsupported claims, and costs to consider [46:45]; and
• More.